MONTREAL, Nov. 9 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. (TSX:CYT), the global leader in cryotherapy products to treat cardiac arrhythmias,today announced that Jan Keltjens, President and CEO of CryoCath, will presentat the Canaccord Adams Cardiovascular Conference at the Waldorf Astoria in NewYork City on Tuesday, November 13 at 11:45 am ET. Mr. Keltjens will present onthe Company's market outlook and discuss some recent events and upcomingmilestones, including the STOP AF IDE Trial for Arctic Front(R), the Company'sminimally invasive cryo-balloon catheter designed specifically to treatparoxysmal atrial fibrillation.
A live webcast of CryoCath's presentation will be available atwww.cryocath.com.
CryoCath - www.cryocath.com - is a medical technology company that leadsthe world in cryotherapy products to treat cardiovascular disease. With apriority focus on providing physicians with a complete solution of catheterproducts to treat cardiac arrhythmias, CryoCath has multiple products approvedin the U.S., across Europe and several ROW countries. The Company isdeveloping additional products to expand its pipeline of products to treatcardiac arrhythmias.
This press release includes "forward-looking statements" that are subjectto risks and uncertainties, including with respect to the timing of regulatorytrials and their outcome. For information identifying legislative orregulatory, economic, climatic, currency, technological, competitive and otherimportant factors that could cause actual results to differ materially fromthose anticipated in the forward looking statements, see CryoCath's annualreport available at www.sedar.com under the heading Risks and Uncertainties inthe Management's Discussion and Analysis section.
SOURCE CryoCath Technologies Inc.